| 臺大學術典藏 |
2021-08-11T03:46:35Z |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. |
| 中山醫學大學 |
2020 |
First-in-Human study of JNJ-55920839 in healthy volunteers and patients with systemic lupus erythematosus: a randomised placebo-controlled phase 1 trial
|
Jordan, J; Benson, J; Chatham, WW; Furie, RA; Stohl, W; Wei, JCC; Marciniak, S; Yao, ZL; Srivastava, B; Schreiter, J; Cesaroni, M; Orillion, A; Seridi, L; Chevrier, M |
| 臺大學術典藏 |
2020-05-26T09:26:20Z |
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials
|
Schuler M;Paz-Ares L;Sequist L.V;Hirsh V;Lee K.H;Wu Y.-L;Lu S;Zhou C;Feng J;Ellis S.H;Samuelsen C.H;Tang W;M?rten A;Ehrnrooth E;Park K;Chih-Hsin Yang; Schuler M; Paz-Ares L; Sequist L.V; Hirsh V; Lee K.H; Wu Y.-L; Lu S; Zhou C; Feng J; Ellis S.H; Samuelsen C.H; Tang W; Märten A; Ehrnrooth E; Park K; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ?�real-world??clinical setting
|
Park K;Wan-Teck Lim D;Okamoto I;Chih-Hsin Yang; Park K; Wan-Teck Lim D; Okamoto I; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:48Z |
First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases
|
Chih-Hsin Yang;Zazulina V;Massey D;Sequist L.V;Popat S;Mok T;Yamamoto N;O'Byrne K;Hirsh V;Wu Y.-L;Schuler M; Schuler M; Wu Y.-L; Hirsh V; O'Byrne K; Yamamoto N; Mok T; Popat S; Sequist L.V; Massey D; Zazulina V; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:20Z |
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
|
Schuler M;Tan E.-H;O??Byrne K;Zhang L;Boyer M;Mok T;Hirsh V;Chih-Hsin Yang;Lee K.H;Lu S;Shi Y;Kim S.-W;Laskin J;Kim D.-W;Arvis C.D;K?lbeck K;Massey D;M?rten A;Paz-Ares L;Park K.; Schuler M; Tan E.-H; O?�Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K. |
| 臺大學術典藏 |
2022-05-10T08:09:28Z |
First-line anaplastic lymphoma kinase (Alk) inhibitors for alk-positive lung cancer in asian populations: Systematic review and network meta-analysis
|
Wu K.-L.; Chen H.-L.; Tsai Y.-M.; Lee T.-H.; Chang H.-M.; Tsai Y.-C.; Chuang C.-H.; Chang Y.-C.; YU-KANG TU; Yang C.-J.; Hung J.-Y.; Chong I.-W. |
| 國家衛生研究院 |
2017-10 |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo, SH;Yeh, KH;Wu, MS;Lin, CW;Wei, MF;Liou, JM;Wang, HP;Chen, LT;Cheng, AL |
| 臺大學術典藏 |
2018-09-10T18:04:32Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo, S.-H. and Yeh, K.-H. and Wu, M.-S. and Lin, C.-W. and Wei, M.-F. and Liou, J.-M. and Wang, H.-P. and Chen, L.-T. and Cheng, A.-L.; JYH-MING LIOU; CHUNG-WU LIN; MING-SHIANG WU; ANN-LII CHENG |
| 臺大學術典藏 |
2020-03-03T03:36:41Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo S.-H.;Yeh K.-H.;Wu M.-S.;Chung-Wu Lin;Wei M.-F.;Liou J.-M.;Wang H.-P.;Chen L.-T.;Cheng A.-L.; Kuo S.-H.; Yeh K.-H.; Wu M.-S.; CHUNG-WU LIN; Wei M.-F.; Liou J.-M.; Wang H.-P.; Chen L.-T.; Cheng A.-L. |
| 臺大學術典藏 |
2020-11-02T02:04:20Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Cheng A.-L.; Chen L.-T.; Wang H.-P.; Liou J.-M.; Wei M.-F.; Lin C.-W.; MING-SHIANG WU; Yeh K.-H.; Kuo S.-H. |
| 臺大學術典藏 |
2021-02-02T02:21:00Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo S.-H.; Yeh K.-H.; MING-SHIANG WU; Lin C.-W.; Wei M.-F.; Liou J.-M.; Wang H.-P.; Chen L.-T.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-23T08:26:17Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Sung-Hsin Kuo;Yeh K.-H.;Wu M.-S.;Lin C.-W.;Wei M.-F.;Liou J.-M.;Wang H.-P.;Chen L.-T.;Cheng A.-L.; SUNG-HSIN KUO; Yeh K.-H.; Wu M.-S.; Lin C.-W.; Wei M.-F.; Liou J.-M.; Wang H.-P.; Chen L.-T.; Cheng A.-L. |
| 臺大學術典藏 |
2021-08-31T06:29:32Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo S.-H.; Yeh K.-H.; Wu M.-S.; Lin C.-W.; Wei M.-F.; Liou J.-M.; Wang H.-P.; Chen L.-T.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-01-15T03:46:33Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo S.-H.; Yeh K.-H.; Wu M.-S.; Lin C.-W.; Wei M.-F.; Liou J.-M.; HSIU-PO WANG; Chen L.-T.; Cheng A.-L. |
| 臺大學術典藏 |
2021-01-28T01:06:22Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo S.-H.;Kun-Huei Yeh;Wu M.-S.;Lin C.-W.;Wei M.-F.;Liou J.-M.;Wang H.-P.;Chen L.-T.;Cheng A.-L.; Kuo S.-H.; KUN-HUEI YEH; Wu M.-S.; Lin C.-W.; Wei M.-F.; Liou J.-M.; Wang H.-P.; Chen L.-T.; Cheng A.-L. |
| 臺大學術典藏 |
2021-05-27T08:20:46Z |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo S.-H.; Yeh K.-H.; Wu M.-S.; Lin C.-W.; Wei M.-F.; JYH-MING LIOU; Wang H.-P.; Chen L.-T.; Cheng A.-L. |
| 國立成功大學 |
2017 |
First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma
|
Kuo, S.-H.;Yeh, K.-H.;Wu, M.-S.;Lin, C.-W.;Wei, M.-F.;Liou, J.-M.;Wang, H.-P.;Chen, L.-T.;Cheng, A.-L. |
| 臺大學術典藏 |
2020-08-12T06:34:32Z |
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
|
Geater S.L.; Wolf J.; Paz-Ares L.; Soria J.-C.; Tan D.S.W.; Chiari R.; Wu Y.-L.; Soria J.-C.;Tan D.S.W.;Chiari R.;Wu Y.-L.;Paz-Ares L.;Wolf J.;Geater S.L.;Orlov S.;Cortinovis D.;Chong-Jen Yu;Hochmair M.;Cortot A.B.;Tsai C.-M.;Moro-Sibilot D.;Campelo R.G.;Mcculloch T.;Sen P.;Dugan M.;Pantano S.;Branle F.;Massacesi C.;De Castro G.;Jr; Orlov S.; Cortinovis D.; CHONG-JEN YU; Hochmair M.; Cortot A.B.; Tsai C.-M.; Moro-Sibilot D.; Campelo R.G.; McCulloch T.; Sen P.; Dugan M.; Pantano S.; Branle F.; Massacesi C.; de Castro G.; Jr |
| 臺大學術典藏 |
2022-06-27T07:00:11Z |
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
|
Soria J.-C.; Tan D.S.W.; Chiari R.; Wu Y.-L.; Paz-Ares L.; Wolf J.; Geater S.L.; Orlov S.; Cortinovis D.; CHONG-JEN YU; Hochmair M.; Cortot A.B.; Tsai C.-M.; Moro-Sibilot D.; Campelo R.G.; McCulloch T.; Sen P.; Dugan M.; Pantano S.; Branle F.; Massacesi C.; de Castro G.; Jr |
| 國立臺灣大學 |
2014 |
First-line Combination Therapy with Rituximab and Corticosteroids is Effective and Safe for Pemphigus
|
Cho, Yung-Tsu; Lee, Fang-Yu; Chu, Chia-Yu; Wang, Li-Fang |
| 臺大學術典藏 |
2019-12-04T08:43:43Z |
First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus
|
Cho Y.-T.;Lee F.-Y.;Chia-Yu Chu;Wang L.-F.; Cho Y.-T.; Lee F.-Y.; CHIA-YU CHU; Wang L.-F. |
| 國立臺灣大學 |
2015 |
First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid
|
Cho, Y. T.; Chu, C. Y.; Wang, L. F.; 王莉芳 |
| 臺大學術典藏 |
2015 |
First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid
|
Cho, Y.T.;Chu, C.Y.;Wang, L.F.; LI-FANG WANG; CHIA-YU CHU |
| 臺大學術典藏 |
2019-12-04T08:43:40Z |
First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid
|
Wang L.F.; Cho Y.T.; CHIA-YU CHU; Cho Y.T.;Chia-Yu Chu;Wang L.F. |
